This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bristol-Myers Squibb's Bold Move

In a replay of an attempt four years ago, Bristol-Myers Squibb (BMY - Get Report) is asking the federal government to allow its prescription cholesterol drug Pravachol to become an over-the-counter medication.

The company is hoping for a better outcome than in 2000. Bristol-Myers Squibb's petition was rejected by advisory committees of the Food and Drug Administration because the company failed to prove the drug could be used safely without a doctor's prescription.

Bristol-Myers Squibb, which announced its latest move after markets had closed Friday, is the second drugmaker to seek the FDA's approval to convert a prescription cholesterol drug to over-the-counter, or OTC, status. Two FDA advisory committees are scheduled to hold joint hearings on Jan. 13 and Jan. 14 on Merck's (MRK - Get Report) request that Mevacor become an OTC drug. At the moment, Pravachol isn't on the advisory committees' calendar.

Mevacor also was rejected as an OTC candidate by FDA advisory panels four years ago.

Bristol-Myers said little about its OTC application except that it has signed an agreement with Germany's Bayer (BAY) to handle OTC sales and marketing for Pravachol in the U.S.

Pravachol is one of the oldest member of the cholesterol drug class known as statins, which includes Mevacor and Zocor.

Merck is working with Johnson & Johnson (JNJ - Get Report) to market OTC Mevacor in the U.S. The two companies are selling a nonprescription version of Merck's Zocor in the U.K., the first country to permit an OTC statin.

Pravachol will lose U.S. patent protection in April 2006. Mevacor has already lost patent protection, and its sales have been significantly eroded by generic competitors.

Last year, Pravachol produced $2.83 billion in sales, or nearly 14% of total corporate revenue at Bristol-Myers Squibb. However, the drug's sales have begun to fade. For the nine months ended Sept. 30, Pravachol recorded $1.93 billion in worldwide sales, down 8% from the same period last year. In the U.S., sales dropped 18% from the same period last year. For the three months ended Sept. 30, worldwide sales fell 24% to $598 million; the U.S. component fell by 31%. (Mevacor's sales are so small that Merck doesn't include them in its quarterly financial press releases.)

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BMY $59.31 -0.35%
JNJ $101.01 -0.68%
MRK $48.45 -0.82%
AAPL $93.99 0.31%
FB $103.16 1.20%


Chart of I:DJI
DOW 15,893.71 +233.53 1.49%
S&P 500 1,847.89 +18.81 1.03%
NASDAQ 4,294.0220 +27.1850 0.64%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs